1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Caregen Co., Ltd.

Caregen Co., Ltd.

KKRX:214370
35,900.00
KRW
-1,400.00
(-3.75%)
467.92EPS
147.25P/E
3.37TMarket Cap
Nov 06Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
636.41
648.52
582.89
910.6
1,001.83
1,297.22
1,223.2
1,205.18
281.79
1,612.76
1,681.69
1,488.87
1,532.19
Basic EPS, GAAP
304.2
274.8
218.2
360.6
322.6
562.8
638.6
516.4
111.2
813
658
411
467.92
Free Cash Flow per Basic Share
300.26
-289.91
-382.06
821.35
-188.03
1,246.25
181.69
950.27
-125.22
384.87
-1,089.12
279.49
438.42
Dividend per Share
- -
- -
121.2
321.35
240.28
- -
704.78
420.01
99.98
580.2
640.33
636.6
236.95
Book Value per Share
1,027.37
4,502.65
4,184.33
4,044.8
4,032.47
4,359.4
4,184.41
4,277.37
4,396.08
4,626.08
4,562.6
4,347.68
4,474.17
Tangible Book Value per Share
1,003.23
4,480.62
4,160.14
4,018.58
4,004.46
4,324.05
4,139.08
4,214.88
4,316.37
4,530.63
4,461.31
4,244.19
4,370.71
Basic Weighted Avg Shares
45
47
53
51
51
50
49
49
245
49
49
49
49
Sales/Revenue/Turnover
28,686
30,234
30,905
46,531
51,211
64,699
60,295
59,088
69,098
79,210
82,586
72,808
74,896
Operating Margin (%)
53.91
45.84
34.59
47.15
38.55
54.68
53.04
47.73
48.66
50.98
41.47
28.02
24.35
Depreciation Expense
908
1,109
1,675
1,915
1,959
2,070
2,084
2,036
3,450
4,982
5,156
5,018
5,123
Net Income, GAAP
13,712
12,811
11,569
18,426
16,491
28,070
31,478
25,318
27,267
39,930
32,314
20,099
22,873
Effective Tax Rate (%)
20.23
26.38
26.86
23.3
27.73
28.01
12.84
25
21.01
19.45
19.55
10.07
13.78
Profit Margin (%)
47.8
42.37
37.43
39.6
32.2
43.39
52.21
42.85
39.46
50.41
39.13
27.6
30.54
Working Capital
28,923
203,499
174,304
155,641
155,365
168,417
135,969
139,479
148,442
155,113
88,340
74,766
80,677
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
55,016
241,117
219,701
210,397
204,672
216,876
205,242
209,794
215,978
227,299
222,978
212,475
218,656
Return on Invested Capital (%)
- -
6.76
3.35
7.68
6.73
11.88
13.11
10.04
12.23
14.36
11.99
8.56
7.36
Return on Capital (%)
- -
8.65
5.11
8.66
8.06
13.34
14.93
12.27
12.83
18.02
14.35
9.23
10.5
Return on Common Equity (%)
- -
8.65
5.07
8.73
8.01
13.31
14.91
12.21
12.81
18.02
14.35
9.23
10.5

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
49
49
Market Capitalization
3,508,922
4,437,467
3,367,197

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
83,143
97,257
92,322
Cash, Cash Equivalents & STI
29,053
37,457
35,561
Accounts Receivable, Net
29,996
34,738
30,815
Inventories
22,603
23,562
23,848
Total Current Liabilities
8,378
20,250
11,645
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.14%
0.76%
-4.71%
Free Cash Flow
-162.82%
-83.15%
-125.55%
Net Income, GAAP
9.91%
-4.46%
-37.8%
Sales/Revenue/Turnover
10.44%
4.4%
-11.84%
Total Cash Common Dividend
- -
0.78%
-1%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20,449
20,462
20,317
21,358
82,586
2025
21,292
18,118
17,088
16,310
72,808
2026
22,704
18,795
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
194
123
238
103.68
658
2025
172
98
207.8
-67.15
411
2026
239.3
88
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
239.93
- -
640.33
2025
- -
- -
237
- -
636.6
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yong-Ji Chung
Full Time Employees
201
Sector
Process industries
Industry
Chemicals: major diversified
Address
46-38, LS-ro 91beon-gil Seoul GY South Korea 14119
IPO Date
Nov 17, 2015
Website
caregen.co.kr
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Caregen Co., Ltd. is a South Korean biotechnology company specializing in the research, development, and commercialization of biomimetic peptides and peptide-based products across multiple healthcare segments. Founded in 2001 and headquartered in Anyang-Si, South Korea, Caregen's main offerings include dermal fillers marketed under brands such as REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600; skin care products under Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert; scalp care products branded Renokin and Pelo Baum; and health foods including proGsterol. In addition, the company develops pharmaceutical treatments and medical equipment addressing conditions like COVID-19, diabetic retinopathy, macular degeneration, hair loss, arthritis, wounds, and obesity, alongside cosmetic applications such as wrinkle improvement, whitening, acne care, and UV protection. Caregen also produces food supplements for blood sugar regulation, liver function improvement, hangover cure, cholesterol control, and body fat reduction. Recent major developments include strategic partnerships and market expansions, notably a joint venture with Indian wellness brand VLCC Health Care Ltd to market Caregen's cosmeceutical products in India and other countries, leveraging VLCC's manufacturing facilities to enhance competitive positioning. Additionally, Caregen entered an in-licensing agreement with Akums Drugs & Pharmaceuticals Ltd, India's largest contract development and manufacturing organization, to launch specialty nutraceuticals, differentiated topical and injectable cosmeceuticals, and pharmaceuticals tailored for the Indian market. These alliances emphasize Caregen's focus on expanding its geographic footprint and product offerings in fast-growing wellness and healthcare sectors. Operating globally with strong presences in Asia, including South Korea, India, and broader markets such as Hong Kong, Japan, Singapore, Taiwan, Europe, and the USA, Caregen maintains a diversified portfolio across cosmeceuticals, Class III medical devices, nutraceuticals, pharmaceuticals, and medical equipment. The company is listed on the Korea Securities Dealers Automated Quotation System (KOSDAQ) since November 2015 and continues to innovate in peptide research with over 600 functional peptides developed, positioning itself as a leader in peptide biotechnology and integrated healthcare solutions.